Development Insulin Pharma Companies Pharmacy 
Pharmaceutical Technology
JULY 15, 2022
Insulin prices made the headlines again as California governor Gavin Newsom announced plans on 7 July for the state to manufacture low-cost insulin. The state plans to work directly with a contract manufacturing organization (CMO) to manufacture low-cost insulin. In-house manufacturing the norm.
pharmaphorum
APRIL 13, 2022
The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products. Ben Hargreaves looks at why insulin’s price is so controversial and whether this could be set to change. Insulin rationing. In the US, approximately 37.3
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT News
MARCH 10, 2023
Enjoy, and see you soon … By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products , STAT explains. Two
XTalks
JANUARY 5, 2024
Among its services, Lilly said LillyDirect provides disease management resources that include access to independent healthcare providers, personalized support and direct delivery of select Lilly medications to homes via third-party pharmacy dispensing services.
pharmaphorum
SEPTEMBER 1, 2020
The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. Merck in Germany was possibly the earliest company to move in this direction. The national rivalries and conflicts that characterised this period also had their impact on the developing industry.
pharmaphorum
JUNE 10, 2021
Nowhere has this need for healthy companies been more apparent than during the current global coronavirus pandemic, with multiple manufacturers making COVID-19 vaccines rapidly available to the public. A key reason for rising drug prices is the role of middlemen, in the form of health plans and pharmacy benefit managers (PBMs).
pharmaphorum
JULY 13, 2022
And while pharma companies are working hard to find treatments for these diseases, they have a major problem that must be addressed before that work can be done effectively: the lack of objective, quantitative measurement tools for assessing the progression – or even the presence or absence – of these conditions.
Expert insights. Personalized for you.
328 
Let's personalize your content